Compare EVO & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | NEO |
|---|---|---|
| Founded | 1993 | 2001 |
| Country | Germany | United States |
| Employees | 4553 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2008 |
| Metric | EVO | NEO |
|---|---|---|
| Price | $3.07 | $10.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $7.00 | ★ $13.38 |
| AVG Volume (30 Days) | 47.1K | ★ 1.3M |
| Earning Date | 04-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.37 | $10.63 |
| Revenue Next Year | $10.05 | $9.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.31 | $4.72 |
| 52 Week High | $4.42 | $13.74 |
| Indicator | EVO | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 74.64 |
| Support Level | $2.88 | $9.35 |
| Resistance Level | $3.75 | $10.66 |
| Average True Range (ATR) | 0.07 | 0.45 |
| MACD | 0.01 | 0.18 |
| Stochastic Oscillator | 89.58 | 95.96 |
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.